Valuation: Cognition Therapeutics, Inc.

Market Cap 98.9M 86.24M 81.43M 73.94M 139M 9.49B 139M 975M 376M 4.82B 372M 363M 15.52B P/E 2026 *
-3.51x
P/E 2027 * -4.73x
Enterprise Value 98.9M 86.24M 81.43M 73.94M 139M 9.49B 139M 975M 376M 4.82B 372M 363M 15.52B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.71%
Yield 2026 *
-
Yield 2027 * -
1 day-1.89%
1 week+5.82%
Current month+0.97%
1 month+8.71%
3 months-28.28%
6 months-2.80%
Current year-22.96%
1 week 0.98
Extreme 0.9812
1.08
1 month 0.96
Extreme 0.96
1.08
Current year 0.55
Extreme 0.5501
1.76
1 year 0.55
Extreme 0.5501
2.05
3 years 0.22
Extreme 0.222301
3.83
5 years 0.22
Extreme 0.222301
13.8
10 years 0.22
Extreme 0.222301
13.8
Manager TitleAgeSince
Chief Executive Officer 66 2020-03-26
Director of Finance/CFO 48 2023-04-30
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 46 2015-06-30
Director/Board Member 69 2016-08-31
Director/Board Member 66 2019-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
5/1/26 Tax

Chief Financial Officer

-8,567 0.0096%
4/16/26 Buy

Chief Executive Officer

9,175 0.0103%
4/16/26 Buy

Chief Financial Officer

10,000 0.0112%
Change 5-day change 1-year change 3-year change Capi.($)
-1.89%+5.82%-25.71%-16.80% 98.9M
-0.31%+5.79%+47.13%+99.53% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+0.50%+7.13%+33.27%+20.02% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.36B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average -0.38%+2.15%+30.34%+189.11% 27.49B
Weighted average by Cap. -0.28%+1.49%+35.66%+150.89%

Financials

2026 *2027 *
Net sales - -
Net income -27.17M -23.69M -22.37M -20.31M -38.06M -2.61B -38.22M -268M -103M -1.33B -102M -99.79M -4.26B -54.95M -47.92M -45.24M -41.09M -76.98M -5.27B -77.3M -542M -209M -2.68B -206M -202M -8.63B
Net Debt - -
Logo Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
Employees
14
Date Price Change Volume
26-09-18 US$1.040 -1.89% 336,701
26-09-17 US$1.060 +3.92% 615,872
26-09-16 US$1.020 -1.45% 531,697
26-09-15 US$1.035 +2.48% 627,288
26-09-14 US$1.010 +2.77% 231,378
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.040USD
Average target price
3.333USD
Spread / Average Target
+220.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGTX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!